Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025)

Caribou Biosciences (CRBU) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $2.2 million as the latest value for Q2 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $2.2 million in Q2 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a N/A change, with the full-year FY2025 number at $12.2 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $2.2 million for Q2 2025 at Caribou Biosciences, down from $9.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $9.2 million in Q1 2025 to a low of $2.2 million in Q2 2025.